Skip to main content

Table1 Clinical characteristics CAF and gastric cancer survival in TCGA cohort

From: Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression

Variates

Cases

Univariate HR 95% CI (P Value)

Multivariate HR 95%CI (P value)

OS

DFS

OS

DFS

Age

< 50(ref)

20

    
 

50

219

0.5409–4.15 (0.437)

0.35–2.25 (0.798)

0.55–4.39 (0.4116)

0.35–2.33 (0.8790)

sex

Female(ref)

94

    
 

male

145

0.68–2.03 (0.562)

0.98–3.87 (0.0557)

0.67–2.03 (0.5917)

1.02–4.05 (0.0440)

Lauren classification

Intestinal(ref)

99

    
 

Diffuse

44

0.61–2.57 (0.538)

0.80–4.18 (0.1686)

0.52–2.35 (0.7959)

0.65–3.76 (0.3134)

 

NOS

95

0.93–3.03 (0.088)

1.17–4.86 (0.0163)

0.81–2.80 (0.1966)

1.07–4.73 (0.0329)

Stage

I/II(ref)

138

    
 

III

101

0.95–2.71 (0.0783)

0.58–1.91 (0.866)

1.02–3.00 (0.0420)

0.62–2.06 (0.7085)

CAF

Low(ref)

73

    
 

Medium

81

1.04–4.66 (0.0389)

0.67–3.66 (0.3037)

0.97–4.57 (0.0591)

0.54–3.10 (0.5632)

 

High

85

1.09–4.73 (0.0285)

1.04–4.91 (0.0398)

1.04–4.71 (0.0391)

0.87–4.24 (0.1081)

  1. OS overall survival, DFS disease-free survival, 95%CI: 95% confidence interval